Details of the Drug

General Information of Drug (ID: DMZXF05)

Drug Name

GTx-024

Synonyms

(R)-Ostarine; 1132656-73-5; (2R)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide; C19H14F3N3O3; 841205-47-8 pound not1202044-20-9; SCHEMBL2197534; CHEBI:94527; DTXSID70649384; BCPP000135; AOB87717; ZINC35793633; BCP9001038; NCGC00408913-01; AS-17044; FT-0673314; Y0247; 370C134; I06-2154; BRD-K16621777-001-01-9; (R)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide

Indication

Disease Entry	ICD 11	Status	REF
Muscle atrophy	FB32.Y	Phase 3	[1]
Breast cancer	2C60-2C65	Phase 2	[2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C19H14F3N3O3
Canonical SMILES: CC(COC1=CC=C(C=C1)C#N)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
InChI: InChI=1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)/t18-/m0/s1
InChIKey: JNGVJMBLXIUVRD-SFHVURJKSA-N

Cross-matching ID

PubChem CID: 11326715
ChEBI ID: CHEMBL1738889
CAS Number: 841205-47-8
UNII: O3571H3R8N
DrugBank ID: DB12078
TTD ID: D0NE3W

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT01355497) Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)